A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback